Forskning
Udskriv Udskriv
Switch language
Rigshospitalet - en del af Københavns Universitetshospital
Udgivet

The Jury Is Still Out on the Benefits and Harms of Methylphenidate for Children and Adolescents With Attention-Deficit/Hyperactivity Disorder

Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

DOI

  1. Oral Chaperone Therapy Migalastat for the Treatment of Fabry Disease: Potentials and Pitfalls of Real-World Data

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  2. Clopidogrel-Paclitaxel Drug-Drug Interaction: A Pharmacoepidemiologic Study

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  3. Comment on: "Cell Therapy for Heart Disease: Trial Sequential Analyses of Two Cochrane Reviews"

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  4. The mitochondria in heart failure: a target for coenzyme Q10 therapy?

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  1. Sertraline in primary care: comments on the PANDA trial

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  2. Beta-blockers for suspected or diagnosed acute myocardial infarction

    Publikation: Bidrag til tidsskriftReviewForskningpeer review

Vis graf over relationer

Much remains unclear about the benefits and harms of methylphenidate for children and adolescents with attention-deficit/hyperactivity disorder (ADHD). Between 2012 and 2018, we conducted two Cochrane systematic reviews on methylphenidate for ADHD. This article explores the main findings in relation to evidence-based practice and our current understanding of ADHD.

OriginalsprogEngelsk
TidsskriftClinical Pharmacology and Therapeutics
Vol/bind104
Udgave nummer4
Sider (fra-til)606-609
ISSN0009-9236
DOI
StatusUdgivet - 13 jul. 2018

ID: 54833158